Editing Myasthenia gravis (section)

====Immune suppressants====
The steroid [[prednisone]] might also be used to achieve a better result, but it can lead to the worsening of symptoms and takes weeks to achieve its maximal effectiveness.<ref name=":1" /> Research suggests that up to 15% of patients do not positively respond to immune suppressants.<ref>{{Cite journal |vauthors=Drachman DB, Adams RN, Hu R, Jones RJ, Brodsky RA |date=2008-06-01 |title=Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis |journal=Annals of the New York Academy of Sciences |volume=1132 |issue=1 |pages=305–314 |bibcode=2008NYASA1132..305D |doi=10.1196/annals.1405.033 |pmc=3390145 |pmid=18567882}}</ref><ref>{{Cite journal |vauthors=Suh J, Goldstein JM, Nowak RJ |date=June 2013 |title=Clinical characteristics of refractory myasthenia gravis patients |journal=The Yale Journal of Biology and Medicine |volume=86 |issue=2 |pages=255–260 |pmc=3670444 |pmid=23766745}}</ref><ref name="auto1" /> Due to the myriad symptoms that steroid treatments can cause, it is not the preferred method of treatment.<ref name=":1" /> Other immune suppressing medications may also be used including [[rituximab]]<ref>{{Cite journal |vauthors=Tandan R, Hehir MK, Waheed W, Howard DB |date=August 2017 |title=Rituximab treatment of myasthenia gravis: A systematic review |journal=Muscle & Nerve |volume=56 |issue=2 |pages=185–196 |doi=10.1002/mus.25597 |pmid=28164324 |s2cid=19504332}}</ref> or [[azathioprine]].<ref name="NIH2016" />

[[Nipocalimab]] (Imaavy) was approved for medical use in the United States in April 2025.<ref>{{cite web | title=Novel Drug Approvals for 2025 | website=U.S. [[Food and Drug Administration]] (FDA) | date=1 May 2025 | url=https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025 | access-date=1 May 2025}}</ref><ref name="JandJ PR 20250430">{{cite press release | title=Johnson & Johnson receives FDA approval for Imaavy (nipocalimab-aahu), a new FcRn blocker offering long-lasting disease control in the broadest population of people living with generalized myasthenia gravis (gMG) | publisher=Johnson & Johnson | via=MultiVu | date=30 April 2025 | url=https://www.multivu.com/johnson-johnson/9331651-en-johnson-johnson-receives-fda-approval-imaavy-nipocalimab-aahu | access-date=1 May 2025}}</ref>